4000: State of the Science of Schizophrenia – What We Know and What We Don’t
Speaker: Mary D. Moller, DNP, APRN, PMHCNS-BC, CPRP, FAAN
Disclosures: Dr. Moller is the recipient of a non-pharmacological grant from Astra Zeneca pharmaceuticals to study the effects of case manager education on outcomes in schizophrenia. There may be discussion of off-label uses of medications presented in this session. The activity planners have no conflicts of interest to disclose.
Session Length: 60 minutes
Target Audience: RN, APRN
Upon completion of this presentation, the participant will be able to:
1. Discuss the 22 known schizophrenia facts based on recent research.
2. Discuss implications of the 2009 Schizophrenia Patient Outcomes Research Team (PORT) Updated Treatment Recommendations.
Continuing Nursing Education
1.0 contact hours. * In order to receive contact hours, you must: Listen to the entire session, complete an evaluation, and earn a passing score on the post test before the expiration date. You will have 5 tries to correctly answer the questions on the post test. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. We cannot award credit unless all steps are completed.
The content of this CNE activity pertains to pharmacology. Because states' requirements may vary, contact your Board of Nursing for more information.
The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Saturday, October 22, 2011: 7:00am – 8:00am
APNA 25th Annual Conference
Release Date: March 2, 2012
The contact hours for this session expire: March 14, 2014